Version 1
: Received: 6 February 2020 / Approved: 8 February 2020 / Online: 8 February 2020 (05:56:31 CET)
How to cite:
Bojin, F.; Gavriliuc, O.; Margineanu, M.; Paunescu, V. Design of an Epitope-Based Synthetic Long Peptide Vaccine to Counteract the Novel China Coronavirus (2019-nCoV). Preprints.org2020, 2020020102
Bojin, F.; Gavriliuc, O.; Margineanu, M.; Paunescu, V. Design of an Epitope-Based Synthetic Long Peptide Vaccine to Counteract the Novel China Coronavirus (2019-nCoV). Preprints.org 2020, 2020020102
Cite as:
Bojin, F.; Gavriliuc, O.; Margineanu, M.; Paunescu, V. Design of an Epitope-Based Synthetic Long Peptide Vaccine to Counteract the Novel China Coronavirus (2019-nCoV). Preprints.org2020, 2020020102
Bojin, F.; Gavriliuc, O.; Margineanu, M.; Paunescu, V. Design of an Epitope-Based Synthetic Long Peptide Vaccine to Counteract the Novel China Coronavirus (2019-nCoV). Preprints.org 2020, 2020020102
Abstract
In this report, we demonstrate that it is possible to design epitope-based peptide vaccine candidates to counteract the novel China coronavirus (2019-nCoV) by using an approach similar to the one used in cancer neoantigen vaccination therapy. We identified multiepitope peptide vaccine candidates against 2019-nCov that can potentially trigger both CD4+ and CD8+ T cell immune response with increased efficiency due to the presence of CD4+ and CD8+ T cell epitopes and a cathepsin-sensitive linker. Furthermore, we suggest that the peptide design strategy should incorporate population-specific HLA alleles in order to optimize binding specificity of the peptides. We refer to this as populationalized vaccinomics.
Biology and Life Sciences, Immunology and Microbiology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
